Moderate-to-severe Chronic Plaque Psoriasis: Clinical Trials

1 active not recruiting, 1 recruiting. 2 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	2	Active not recruiting 1, Recruiting 1
Phase 2	1	Active not recruiting 1

Follow Moderate-to-severe Chronic Plaque Psoriasis: new trials by email Literature Review of Moderate-to-severe Chronic Plaque Psoriasis trials Research Report on Moderate-to-severe Chronic Plaque Psoriasis

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis Ponesimod - Moderate-to-severe Chronic Plaque Psoriasis	Phase 3	Recruiting	Vanda Pharmaceuticals	300	2026-02-17	2026-09-22
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis Tildrakizumab, Placebo, Etanercept - Moderate-to-severe Chronic Plaque Psoriasis	Phase 2 / Phase 3	Active not recruiting	Sun Pharmaceutical Industries Limited	135	2020-01-15	2026-04-15

Narrower conditions

Psoriasis (1)

Broader conditions

Skin Diseases (1)  ·  Skin Diseases, Papulosquamous (1)  ·  Skin and Connective Tissue Diseases (1)

Interventions

Etanercept (1)  ·  ponesimod (1)  ·  tildrakizumab (1)

Sponsors

Sun Pharmaceutical Industries Limited (1)  ·  Vanda Pharmaceuticals (1)

Countries

United States (2)  ·  Hungary (1)  ·  India (1)  ·  Poland (1)  ·  Slovakia (1)  ·  Spain (1)